Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches

Reuters

05-27

Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches

Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538660334"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538660334\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538660334?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538660334","market":"nz","top_or_hot":-1,"title":"Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-27 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2pX4sg:1","article_id":"2538660334","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538660334","pubTimestamp":1748349023,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"随着凯雷和SK Capital收购截止日期的临近，蓝鸟生物敦促股东投标股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLUE":0.9},"content_text":"Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches\n    \n\n        Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluebird Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250527213734) on May 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}